Tags

Type your tag names separated by a space and hit enter

Breast cancer incidence and hormone replacement therapy: results from the MISSION study, prospective phase.
Gynecol Endocrinol. 2007 Jul; 23(7):391-7.GE

Abstract

BACKGROUND

The MISSION Study (Menopause: Risk of Breast Cancer, Morbidity and Prevalence) is a historical-prospective study with random patient selection to determine breast cancer incidence in postmenopausal women with or without hormone replacement therapy (HRT). The first prospective follow-up phase started on 5 January 2004 and the cut-off date for data collection was 30 June 2006.

PARTICIPANTS

Patients were divided into two groups: an 'exposed group' of women on HRT regimens commonly prescribed in France or who had stopped < or =5 years previously; and an 'unexposed group' of women who had never received HRT or stopped >5 years previously. In total 6755 patients were included; and prospective data were available for 4949 patients: 2693 in the exposed group and 2256 in the unexposed group. Women in the exposed group were younger, less overweight, and had fewer first-degree family histories of breast cancer than women of the unexposed group. Mean duration of HRT exposure was 8.3 years, with 31% being exposed for > or =10 years.

RESULTS

The incidence of new breast cancer cases was 0.64% in the exposed group and 0.70% in the unexposed group (relative risk RR(exposed/unexposed) = 0.914, 95% confidence interval = 0.449-1.858; not modified when adjusted for age). Mean age at breast cancer diagnosis was similar in both groups. Breast cancer incidence in the exposed group was not significantly affected by the route of estradiol administration (cutaneous 0.69%; oral 0.52%) or HRT type (estradiol alone 0.28%; estradiol + progesterone 0.40%; estradiol + synthetic progestin 0.94%).

CONCLUSION

No evidence was found for an increased risk of breast cancer in women exposed to HRT compared with non-exposed women.

Authors+Show Affiliations

Hôpital Saint-Louis, Paris, France.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

17701770

Citation

Espié, Marc, et al. "Breast Cancer Incidence and Hormone Replacement Therapy: Results From the MISSION Study, Prospective Phase." Gynecological Endocrinology : the Official Journal of the International Society of Gynecological Endocrinology, vol. 23, no. 7, 2007, pp. 391-7.
Espié M, Daures JP, Chevallier T, et al. Breast cancer incidence and hormone replacement therapy: results from the MISSION study, prospective phase. Gynecol Endocrinol. 2007;23(7):391-7.
Espié, M., Daures, J. P., Chevallier, T., Mares, P., Micheletti, M. C., & De Reilhac, P. (2007). Breast cancer incidence and hormone replacement therapy: results from the MISSION study, prospective phase. Gynecological Endocrinology : the Official Journal of the International Society of Gynecological Endocrinology, 23(7), 391-7.
Espié M, et al. Breast Cancer Incidence and Hormone Replacement Therapy: Results From the MISSION Study, Prospective Phase. Gynecol Endocrinol. 2007;23(7):391-7. PubMed PMID: 17701770.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Breast cancer incidence and hormone replacement therapy: results from the MISSION study, prospective phase. AU - Espié,Marc, AU - Daures,Jean-Pierre, AU - Chevallier,Thierry, AU - Mares,Pierre, AU - Micheletti,Marie-Christine, AU - De Reilhac,Pia, PY - 2007/8/19/pubmed PY - 2007/11/14/medline PY - 2007/8/19/entrez SP - 391 EP - 7 JF - Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology JO - Gynecol. Endocrinol. VL - 23 IS - 7 N2 - BACKGROUND: The MISSION Study (Menopause: Risk of Breast Cancer, Morbidity and Prevalence) is a historical-prospective study with random patient selection to determine breast cancer incidence in postmenopausal women with or without hormone replacement therapy (HRT). The first prospective follow-up phase started on 5 January 2004 and the cut-off date for data collection was 30 June 2006. PARTICIPANTS: Patients were divided into two groups: an 'exposed group' of women on HRT regimens commonly prescribed in France or who had stopped < or =5 years previously; and an 'unexposed group' of women who had never received HRT or stopped >5 years previously. In total 6755 patients were included; and prospective data were available for 4949 patients: 2693 in the exposed group and 2256 in the unexposed group. Women in the exposed group were younger, less overweight, and had fewer first-degree family histories of breast cancer than women of the unexposed group. Mean duration of HRT exposure was 8.3 years, with 31% being exposed for > or =10 years. RESULTS: The incidence of new breast cancer cases was 0.64% in the exposed group and 0.70% in the unexposed group (relative risk RR(exposed/unexposed) = 0.914, 95% confidence interval = 0.449-1.858; not modified when adjusted for age). Mean age at breast cancer diagnosis was similar in both groups. Breast cancer incidence in the exposed group was not significantly affected by the route of estradiol administration (cutaneous 0.69%; oral 0.52%) or HRT type (estradiol alone 0.28%; estradiol + progesterone 0.40%; estradiol + synthetic progestin 0.94%). CONCLUSION: No evidence was found for an increased risk of breast cancer in women exposed to HRT compared with non-exposed women. SN - 0951-3590 UR - https://www.unboundmedicine.com/medline/citation/17701770/Breast_cancer_incidence_and_hormone_replacement_therapy:_results_from_the_MISSION_study_prospective_phase_ L2 - http://www.tandfonline.com/doi/full/10.1080/09513590701382104 DB - PRIME DP - Unbound Medicine ER -